The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy
- PMID: 32421292
- PMCID: PMC7363378
- DOI: 10.1097/PRA.0000000000000475
The 5% of the Population at High Risk for Severe COVID-19 Infection Is Identifiable and Needs to Be Taken Into Account When Reopening the Economy
Abstract
The goal of this column is to help mental health care professionals understand coronavirus disease 2019 (COVID-19) so that they can better explain the complexities of the current crisis to their patients. The bottom-line of this column is that, while COVID-19 can infect virtually everyone in the human population, only about 5% are susceptible to severe infection requiring admission to an intensive care unit and/or causing a fatal outcome and this population can be identified on the basis of comorbid medical illness and/or age. These numbers are based on experience in China, the United States, and Europe. Table 1 presents an analysis conducted by the US Centers for Disease Control and Prevention (CDC), which is further supported by several other sources reviewed in the article. The population at risk for severe infection are individuals with comorbid medical illness and those 85 years of age and older. The comorbid medical illnesses identified as risk factors are preexisting respiratory and cardiovascular disease, immunocompromised status, morbid obesity (ie, body mass index ≥40), diabetes mellitus, and possibly significant kidney or liver impairment. Parenthetically, news reports and the literature sometimes cite age 60 years and older as a risk factor but age between 60 and 85 years is likely a surrogate for having 1 or more of these comorbid medical conditions. While 5% may initially seem like a small number, it nevertheless potentially represents 16.5 million people, given the United States population of 330 million. That is a tremendous number of people requiring intensive care unit admission and/or potentially dying, and individuals in this population have overwhelmed the US health care system in some hotspots. For this reason, this column suggests taking this at-risk population into account in mitigation strategies when attempting to open the US economy. The column addresses the following questions: (1) What are the 3 aspects of the race to minimize the damage caused by COVID-19? (2) What data are currently available to help guide decisions to be made? (3) What strategies have been employed to date and how successful have they been? and (4) Might risk stratification of exposure be a viable strategy to minimize the damage caused by the virus? The race to minimize the damage caused by COVID-19 requires that we obtain knowledge about the disease and its treatment or prevention, how to best safeguard public health and avoid overwhelming the health care system, and how to minimize the societal damage caused by substantial disruption of the economy. Data gathered over the past 4 months since the COVID-19 virus emerged as a human pathogen have provided guidance for our decisions going forward. The most widely adopted strategies for dealing with the COVID-19 pandemic to date have involved the epidemiological approach of encouraging good hygiene practices and social distancing, including orders to "shelter in place," quarantine of high-risk individuals, and isolation of infected individuals. The goal of this epidemiological approach has been to "flatten the curve" by reducing the height of the peak of the infection to avoid overwhelming the health care system and society in general, while buying time to learn more about the disease and find more effective ways to deal with it. However, now that more is known about COVID-19 and the portion of the population that is most at risk for serious adverse outcomes including death, it may be possible to move from a shelter-in-place approach for the entire population to focus on those at most risk and thus facilitate a gradual and rational phased reduction of social restrictions to reopen the economy. Such a graduated opening would be based on regions of countries meeting specific criteria in terms of being able to contain the virus, coupled with vigorous monitoring to look for outbreaks, followed by case monitoring, isolation of infected individuals and quarantine of exposed individuals, and increased use of testing for active disease as well as for immunity. Taking the data on high-risk individuals into account would allow for a gradual lifting of restrictions on the majority of the population while maintaining more stringent safeguards to protect the vulnerable portion of the population. Nevertheless, the entire population would need to continue to practice good hygiene and social distancing while simultaneously-and perhaps even more vigorously-focusing on sheltering the vulnerable population until adequate community immunity has been achieved to prevent the spread of the virus, whether that is accomplished through natural exposure alone or with the addition of safe and effective vaccine(s) which may not be available for a year. Continued widespread testing for antibodies will help determine how far or close this country is-and other countries are-from developing effective community immunity.
Conflict of interest statement
Over his 40-year career, S.H.P. has worked with over 140 pharmaceutical and biotech companies in the United States and throughout the world. Over the past year, he has received grants/research support from or has served as a consultant, on the advisory board, or on the speaker’s bureau for Alkermes, BioXcel, Eisai, Janssen, National Institute of Mental Health, Sunovion, and Usona Institute. All clinical trial and study contracts were with and payments made to The University of Kansas Medical Center Research Institute, a research institute affiliated with The University of Kansas School of Medicine-Wichita.
Similar articles
-
Impact of self-imposed prevention measures and short-term government-imposed social distancing on mitigating and delaying a COVID-19 epidemic: A modelling study.PLoS Med. 2020 Jul 21;17(7):e1003166. doi: 10.1371/journal.pmed.1003166. eCollection 2020 Jul. PLoS Med. 2020. PMID: 32692736 Free PMC article.
-
Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas (Archived).2023 Jan 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jan 25. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 34662052 Free Books & Documents.
-
Quarantine alone or in combination with other public health measures to control COVID-19: a rapid review.Cochrane Database Syst Rev. 2020 Apr 8;4(4):CD013574. doi: 10.1002/14651858.CD013574. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2020 Sep 15;9:CD013574. doi: 10.1002/14651858.CD013574.pub2. PMID: 32267544 Free PMC article. Updated.
-
Spring in London with Covid-19: a personal view.Med Leg J. 2020 Jul;88(2):57-64. doi: 10.1177/0025817220923692. Epub 2020 Jun 9. Med Leg J. 2020. PMID: 32515258
-
Systematic Review of Clinical Insights into Novel Coronavirus (CoVID-19) Pandemic: Persisting Challenges in U.S. Rural Population.Int J Environ Res Public Health. 2020 Jun 15;17(12):4279. doi: 10.3390/ijerph17124279. Int J Environ Res Public Health. 2020. PMID: 32549334 Free PMC article.
Cited by
-
The road to recovery: Sensing public opinion towards reopening measures with social media data in post-lockdown cities.Cities. 2023 Jan;132:104054. doi: 10.1016/j.cities.2022.104054. Epub 2022 Nov 3. Cities. 2023. PMID: 36345535 Free PMC article.
-
Assessing public knowledge, attitudes and determinants of third COVID-19 vaccine booster dose acceptance: current scenario and future perspectives.J Pharm Policy Pract. 2022 Mar 28;15(1):26. doi: 10.1186/s40545-022-00422-2. J Pharm Policy Pract. 2022. PMID: 35346377 Free PMC article.
-
Features of Pathobiology and Clinical Translation of Approved Treatments for Coronavirus Disease 2019.Intervirology. 2022;65(3):119-133. doi: 10.1159/000520234. Epub 2021 Oct 25. Intervirology. 2022. PMID: 34666335 Free PMC article. Review.
-
Place of distancing measures in containing epidemics: a scoping review.Libyan J Med. 2022 Dec;17(1):2140473. doi: 10.1080/19932820.2022.2140473. Libyan J Med. 2022. PMID: 36325628 Free PMC article.
-
Vaccine effectiveness to protect against moderate or severe disease in COVID cases: A prospective cohort study.Med J Armed Forces India. 2022 Apr 4;79(Suppl 1):S102-11. doi: 10.1016/j.mjafi.2022.02.001. Online ahead of print. Med J Armed Forces India. 2022. PMID: 35400799 Free PMC article.
References
-
- National Institute of Allergy and Infectious Diseases (NIAID). Coronaviruses. Bethesda, MD: NIAID; April 9, 2020. Available at: www.niaid.nih.gov/diseases-conditions/coronaviruses Accessed April 20, 2020.
-
- Wikipedia. Severe acute respiratory syndrome. Available at: https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome Accessed April 20, 2020.
-
- Wikipedia. Coronavirus. Available at: https://en.wikipedia.org/wiki/Coronavirus Accessed April 20,2020.
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous